|
T7527 |
Frentizole
|
|
Beta Amyloid
|
|
Frentizole, an immunosuppressive agent, is an inhibitor of the Aβ-ABAD interaction |
|
T77491 |
Prezalumab
|
AMG 557 |
Others
|
|
Prezalumab (AMG 557) is a human IgG2 monoclonal antibody against ICOSL and BAFF. Prezalumab can be used to study sjogren's syndrome cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis and sys... |
|
T76957 |
Belimumab
|
LymphoStat B |
TNF
|
|
Belimumab(LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF).Belimumab is used in the study of fatigue and in the treatment of lupus nephritis and systemic lupus erythematosu... |
|
T3620 |
Solcitinib
|
GLPG-0778,GSK-2586184 |
JAK
|
|
Solcitinib (GLPG-0778) (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus. |
|
T77727 |
Feeblin
|
IRF5-IN-1 |
Others
|
|
Feeblin（IRF5-IN-1） is a protein degradation inducer that specifically blocks pro-inflammatory signaling pathways associated with autoimmune diseases and can be used to study immune system disorders in the class of system... |
|
T77432 |
Anifrolumab
|
MDX-1333,MEDI-546 |
IFNAR
|
|
Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatm... |
|
T0860L |
Mefloquine
|
Ro215998,WR 142490,Ro-215998,Lariam,Ro 215998 |
Others
|
|
Mefloquine (Ro 215998), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic l... |
|
T7310 |
Paquinimod
|
ABR 25757 |
Others
|
|
Paquinimod (ABR 25757) is a S100A9 inhibitor preventing S100A9 binding to TLR-4. |
|
T33883 |
Paramethasone Acetate
|
NCGC00185748-01,Monocortin,CHEBI:31963,8X50N88ZDP,UNII-8X50N88ZDP |
Others
|
|
Paramethasone Acetate is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects that can be used in the treatment of systemic lupus erythematosus. |
|
T81259 |
Rontalizumab
|
RhuMab IFNalpha,Anti-Human IFN alpha Recombinant Antibody |
|
|
Rontalizumab, a humanized IgG1 monoclonal antibody, targets IFN-α and is utilized in research on systemic lupus erythematosus[1]. |
|
T76825 |
Ruplizumab
|
|
|
|
Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease [1]. |
|
T63284 |
PAD-IN-2
|
|
|
|
PAD-IN-2 is a potent inhibitor of pad4 with an IC50 value <1 μM and can be used to study autoimmune diseases and cancers such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, cutaneous lupus erythematos... |
|
T72653 |
(R)-Elsubrutinib
|
(R)-ABBV-105 |
|
|
(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is employed in research related to immune disorders (including rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer. |
|
T83217 |
Abetimus
|
LJP 394 free base |
|
|
Abetimus (LJP 394 free base), an immunosuppressant composed of four double-stranded DNA (dsDNA) oligonucleotides, can crosslink anti-dsDNA antibodies on B cell surfaces and reduce anti-dsDNA antibody levels, offering res... |
|
T76762 |
Tabalumab
|
|
|
|
Tabalumab (LY2127399), a humanized monoclonal antibody (IgG4 type) targeting B-cell activating factor (BAFF), exhibits neutralizing activity against both membrane-bound and soluble BAFF. This compound is relevant for res... |
|
T73651 |
Forigerimod TFA
|
|
|
|
Forigerimod TFA (IPP-201101 TFA), a CD4 T-cell modulator, is a phosphorylated 21-amino-acid fragment derived from U1 small nuclear ribonucleoprotein 70 kDa, specifically at Ser140. It notably inhibits autophagy and is ut... |
|
T72035 |
TLR7/8/9 antagonist 2
|
|
TLR
|
|
TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/... |
|
T74907 |
ODN 21595
|
|
|
|
ODN 21595, a guanine-modified inhibitor targeting TLR7 and TLR9, effectively inhibits the release of IFN-α and IL-6 without exhibiting cytotoxicity. It also reduces the expression of CD86 and HLA-DR, showcasing potential... |
|
T76834 |
Toralizumab
|
|
|
|
Toralizumab (IDEC-131), a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consists of human gamma 1 heavy chains and human kappa light chains. Specifically targeting CD40L on T cells, it inhibits CD40... |
|
T80880 |
Valziflocept
|
BAX1810,TAK-752 |
|
|
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed to act as a "decoy" or "scavenger" by targeting Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigatin... |
|
T73650 |
Forigerimod
|
|
|
|
Forigerimod (IPP-201101), a potent CD4 T-cell modulator, is a 21-amino-acid fragment of the U1 small nuclear ribonucleoprotein 70 kDa, phosphorylated at Ser140, known for its ability to inhibit autophagy effectively. It ... |
|
T82797 |
C5aR1 antagonist peptide
|
|
|
|
C5aR1 antagonist peptide, a biologically active linear peptide originating from the C-terminus of the chemokine complement fragment 5 anaphylatoxin (C5a), inhibits C5a binding and activity at human and rat C5a receptors.... |
|
T76300 |
Edratide
|
|
|
|
Edratide (TV 4710), a 19-amino-acid synthetic peptide derived from the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that exhibits the 16/6 Id idiotype, has been found to lower apoptosis rates ... |
|
T83714 |
LAP TFA
|
Lupus Autoantigen Peptide,La Peptide |
|
|
Lupus autoantigen peptide (LAP), a derivative of the autoantigen La found in systemic lupus erythematosus (SLE) patients, spans amino acids 11-28 of La and functions as an antiviral peptide. It primarily blocks the hepat... |
|
T37419 |
Zetomipzomib
|
|
|
|
KZR-616, a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. KZR-616 has the potential f... |
